Skip to content
MarketScale
‹ Back to IndustriesHealthcare

WHY 2018 IS THE YEAR TO GET YOUR DIGESTIVE TRACT BACK ON TRACK

You may be surprised to learn that your body is jam packed with trillions of bacteria. But don’t worry, most of these bacteria in your body are located in your gut, and they are actually doing good work for you! This little ecosystem, referred to as the gut microbiome, is constantly working to improve your digestion, enhance…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

You may be surprised to learn that your body is jam packed with trillions of bacteria. But don’t worry, most of these bacteria in your body are located in your gut, and they are actually doing good work for you! This little ecosystem, referred to as the gut microbiome, is constantly working to improve your digestion, enhance your immune system, and protect you from harmful bacteria, all three of which are great reasons to focus on improving your gut health this year. The impact of gut health on overall well-being has been a very newsworthy topic in recent years. If you’ve been following the research and developments up until now, but haven’t taken the next step, then 2018 should be your year to do so, and here’s why.

The positive impact of a healthy gut has been proven time and time again. The gut microbiome contains thousands of different kinds of microbes, and is unique to each person. Strains of both good and bad bacteria exist in a delicate balance that effects your whole body. Not enough good bacteria, and functions such as digestion begin to degrade, leading to poor nutrient absorption, gas and bloating, even mental fogginess and weight fluctuations. With more good bacteria, functions such as digestion obviously improve, along with other functions that occur outside your gut, such as your ability to burn and store fat.

A healthy gut is not achieved from its bacterial make-up alone. Enzymes work with the gut microbiome to break down food into absorbable nutrients. If the body experiences a digestive enzyme deficiency, a healthy diet can go to waste as nutrients are not broken down and put to use in the body.

One of the most universally recommended methods to improve your gut health is through the use of enzymes and probiotics, good bacteria, either in foods or supplements. Without a healthy gut, a healthy diet can only go so far.

The long-term effects of a healthy gut can impact every part of your life. The GI tract is almost like a second brain, affecting moods, energy levels, libido, creative output, etc. Gastrointestinal health is extremely important to your overall well-being, which is why enzymes and probiotics are essential to restoring your intestines to a more optimal state. This can be achieved through both enzyme-rich raw foods and supplements.

But simply purchasing any supplement won’t solve your problems. When buying supplements, it is important to look at what they contain, and how much of it. When it comes to probiotics, be sure to check the specific strains and the Colony Forming Unit (CFU) number, which indicates the number of viable bacterial cells in each serving, to make sure that the supplement you choose is powerful enough to impact the flora in your gut. For enzymes, be aware that the potency of these ingredients isn’t measured in milligrams as you may be accustomed to seeing, but instead in varying Activity Units. A supplement facts panel that lists its enzymes measured by weight (in milligrams) may not have a high enough activity to make the difference you’re seeking.

Whether your preferred delivery method is foods or supplements, improving your gut health should be resolution #1 for a healthier 2018.

Deerland Enzymes & Probiotics is a leading specialty formulator and contract manufacturer of enzyme- and probiotic-based dietary supplements. With a team of industry experts working in a state-of-the-art lab, we’re positioned to serve customers from the initial stages of product conceptualization, through the design phase, and on to final formulation and contract manufacturing.

Read more at deerlandenzymes.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512